Omslagafbeelding van de show Science Custom Publishing

Science Custom Publishing

Podcast door Science Custom Publishing

Engels

Technologie en Wetenschap

Tijdelijke aanbieding

2 maanden voor € 1

Daarna € 9,99 / maandElk moment opzegbaar.

  • 20 uur luisterboeken / maand
  • Podcasts die je alleen op Podimo hoort
  • Gratis podcasts
Begin hier

Over Science Custom Publishing

Hear from some of the greatest minds in science on a range of topics in conversation with editors from Science custom publishing.

Alle afleveringen

2 afleveringen

aflevering AI meets medicine: How academic–industry alliances are accelerating drug discovery artwork

AI meets medicine: How academic–industry alliances are accelerating drug discovery

Artificial intelligence (AI) is no longer a futuristic vision in drug discovery. It’s rapidly transforming every stage of the process, from uncovering disease biology to designing new molecules and optimizing clinical trials. In this podcast from the Science/AAAS Custom Publishing Office and sponsored by AstraZeneca, Senior Editor Erika Berg interviews AstraZeneca’s Chief Data Scientist and Vice President Data Science & AI, BioPharmaceuticals R&D, Jim Weatherall and Stanford University’s Professor of Bioengineering, Genetics, Medicine and Biomedical Data, Russ Altman, on how AI is revolutionizing the way we discover and deliver potentially life-saving therapies. With bespoke AI tools now embedded in research and development, scientists can generate novel insights to help accelerate therapeutic development. But this revolution isn’t happening in a vacuum. Weatherall and Altman delve into why collaboration between academia and industry is essential for accelerating innovation while maintaining scientific rigor, ethical safeguards, and a human-centered approach. They discuss how trust, transparency, and a shared mission are shaping a new collaborative model, one that can drive faster, smarter, and more equitable medical breakthroughs in the age of AI.

4 sep 2025 - 28 min
aflevering Investing in cell therapy for solid tumors artwork

Investing in cell therapy for solid tumors

Progress in the development of cell therapies for the treatment of a range of diseases is accelerating, helped along by advancements in gene editing and manufacturing techniques. Pharmaceutical company AstraZeneca has been investing heavily in cell therapy technologies for the treatment of cancer, particularly solid tumors that pose distinct challenges, and is looking to make contributions to patient care. In this podcast from the Science custom publishing office and funded by Astrazeneca, Senior Editor Erika Berg interviews Mark Cobbold, Senior Vice President of Discovery and the Head of Oncology Cell Therapy at AstraZeneca. They explore the future of cell therapy in cancer treatment, the science behind "living medicines," and the vision of scalable, off-the-shelf cell therapies. This episode is a must-listen for anyone passionate about the future of oncology and personalized medicine.

11 dec 2024 - 23 min
Meld je aan om te luisteren
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Makkelijk in gebruik!
App ziet er mooi uit, navigatie is even wennen maar overzichtelijk.

Kies je abonnement

Meest populair

Tijdelijke aanbieding

Premium

20 uur aan luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

2 maanden voor € 1
Daarna € 9,99 / maand

Begin hier

Premium Plus

Onbeperkt luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 7 dagen gratis
Daarna € 13,99 / maand

Probeer gratis

Alleen bij Podimo

Populaire luisterboeken

Begin hier

2 maanden voor € 1. Daarna € 9,99 / maand. Elk moment opzegbaar.